180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the company's previously issued warrants that allow holders to purchase shares of the company's common stock. The warrants, which have an exercise price of $3.23 per share, are exercisable until February 16, 2029. This filing ensures that the information in the registration statement is current and updates the prospectus attached to the Post-Effective Amendment No. 1. The registration statement covers the 242,915 August 2023 Common Warrants and the common stock issuable upon their exercise. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. The company's common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'.

180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the company's previously issued warrants that allow holders to purchase shares of the company's common stock. The warrants, which have an exercise price of $3.23 per share, are exercisable until February 16, 2029. This filing ensures that the information in the registration statement is current and updates the prospectus attached to the Post-Effective Amendment No. 1. The registration statement covers the 242,915 August 2023 Common Warrants and the common stock issuable upon their exercise. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. The company's common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'.